TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03117309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 240 mg
Description: PART A Nivolumab 240 mg IV every 2 weeks x 6 then initial disease assessment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab 1mg/kg
Description: Ipilimumab 1 mg/kg every 3 weeks x 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 3mg/kg
Description: In combination with Ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 360mg
Description: Continue Nivolumab 360 mg IV every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 360mg
Description: Continue Nivolumab 360 mg IV every 3 weeks
Study: NCT01068717

Intervention type: DRUG
Group type: OTHER
Intervention: Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state)
Description: Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week

Intervention type: DRUG
Group type: OTHER
Intervention: Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state)
Description: Tablets, oral, 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC), once daily, 1 week

Intervention type: DRUG
Group type: OTHER
Intervention: Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)
Description: Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week

Intervention type: DRUG
Group type: OTHER
Intervention: Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fed state)
Description: Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin FDC, once daily, 1 week
Study: NCT03810521

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord derived-mesenchymal stromal cells
Description: Intra-articular infiltration of umbilical cord derived-mesenchymal stromal cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord derived-mesenchymal stromal cells
Description: Intra-articular infiltration of umbilical cord derived-mesenchymal stromal cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord derived-mesenchymal stromal cells
Description: Intra-articular infiltration of umbilical cord derived-mesenchymal stromal cells
Study: NCT01359852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C] JNJ-42491293
Description: Part B:\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection, have a 90 minute PET scan and have arterial and venous blood sampling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C] JNJ-42491293 + JNJ-40411813
Description: Part C:\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v.bolus injection. Volunteers will be pre-treated with JNJ-40411813 between 1.5 to 3 hours prior to the second and prior to the third PET scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C] JNJ-42491293 + JNJ-40411813
Description: Part D:\[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection.~Volunteers will be treated with a single dose of up to 500 mg JNJ-40411813 prior to the second scan and will have a third scan at least 2 hours later to evaluate the rate of clearance of JNJ-40411813 from the brain

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C] JNJ-42491293
Description: Part A: \[11C\] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection and have a 120 minute PET scan.
Study: NCT02840435

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sit to Quit
Description: Sit to Quit(STQ) is a smoking cessation program adapted from Mindfulness Training for Smokers (MTS) with core content available on the STQ video. STQ contains many elements found in traditional interventions (e.g. instruction on planning and structuring a quit day, garnering support from others, assessment of prior relapse occasions, development of strategies to avoid triggers). In addition, STQ provides instruction in various mindfulness practices and in how to apply mindfulness skills to manage common causes of relapse. Exercises are provided, and it is recommended to learn the skill experientially. STQ requests that participants practice guided meditation each day using an audio recording and employ other mindfulness practices targeted to manage relapse challenges. Participants will also receive the STQ Participant Manual, which provides all the instruction found in the STQ Video, but provides additional discussion of topics for smokers who desire additional material.
Study: NCT02551536

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Description: group B received FDC tablet of montelukast 10mg and fexofenadine 120 mg O.D

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocetrizine
Description: group A recieved FDC tablet of montelukast 10 mg and levocetrizine 5mg O.D
Study: NCT00006017

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: becatecarin
Description: Arm I: Patients receive rebeccamycin analogue IV over 1 hour on day 1. Arm II: Patients receive rebeccamycin analogue IV over 1 hour on days 1-5. Treatment for both arms repeats every 3 weeks for 6-8 courses in the absence of disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: becatecarin
Description: Arm I: Patients receive rebeccamycin analogue IV over 1 hour on day 1. Arm II: Patients receive rebeccamycin analogue IV over 1 hour on days 1-5. Treatment for both arms repeats every 3 weeks for 6-8 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT04613700

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secretin
Description: Native hormone

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT00861770

Intervention type: OTHER
Group type: OTHER
Intervention: Ultrafiltration
Description: Ultrafiltration based on standard of care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrafiltration using BVM
Description: Ultrafiltration will be guided by blood volume measurement results.
Study: NCT02840435

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quit for Life
Description: Quit for Life integrates telephone counseling, written materials, NRT, and an online program called Web Coach. Web Coach is an interactive internet-based support system that provides health information on smoking cessation, assistance in the development of quit strategies, and an interactive blog to interact with other smokers. Web Coach is used by approximately 70% of AWI callers. Web Coach is not a complete program, but instead is designed to supplement AWI phone-based therapy. In addition, Quit for Life also provides the Quit Guide, which is a smoking cessation manual with written instructions on the use of medications, planning a quit day, and cessation-related cognitive skills.
Study: NCT01628978

Intervention type: OTHER
Intervention: determination by auscultation
Description: determination of depth of endotracheal tube placement by auscultation

Intervention type: OTHER
Intervention: determination by ultrasound
Description: determination of depth of endotracheal tube placement by ultrasound
Study: NCT03210246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY 1002670)
Description: Multiple doses of Vilaprisan for 3 cycles of 28 days each and 7 additional doses on the 7 days after cycle 3.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vilaprisan Placebo
Description: Multiple doses of placebo for 3 cycles of 28 days each and 7 additional doses on the 7 days after cycle 3.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microgynon
Description: Multiple doses of Microgynon for 3 cycles of 21 days each (day 1-21)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon
Description: Multiple doses of Microgynon for 3 cycles of 21 days each (day 1-21)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microgynon Placebo
Description: For the treatment cycle 1-3, 7 doses of Microgynon placebo on Day 22-28 per cycle and after 3 treatment cycles 7 additional doses of Microgynon placebo on the 7 days after cycle 3 (day 84 - 91).
Study: NCT03043209

Intervention type: GENETIC
Intervention: Genomic sequencing
Description: Genomic sequencing of DNA in Blood sample and myectomy tissue
Study: NCT02033681

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One-per-mil Tumescent Solution Injection
Description: One-per-mil tumescent solution containing 1:1,000,000 epinephrine concentration in saline solution, is injected to the finger.
Study: NCT03210246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon Placebo
Description: For the treatment cycle 1-3, 7 doses of Microgynon placebo on Day 22-28 per cycle and after 3 treatment cycles 7 additional doses of Microgynon placebo on the 7 days after cycle 3 (day 84 - 91).
Study: NCT03815942

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1-MVA 5T4 vaccine
Description: ChAdOx1.5T4 will be administered intramuscularly in an extremity (e.g. thigh) at a dose of 2.5 x10\^10 virus particles followed by MVA.5T4 administered via the same route at the dose of 2x10\^8 plaque forming units

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1-MVA 5T4 vaccine
Description: ChAdOx1.5T4 will be administered intramuscularly in an extremity (e.g. thigh) at a dose of 2.5 x10\^10 virus particles followed by MVA.5T4 administered via the same route at the dose of 2x10\^8 plaque forming units

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Infusion [Opdivo]
Description: Nivolumab is to be administered as a flat dose of 480 mg over approximately 60-minutes via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Infusion [Opdivo]
Description: Nivolumab is to be administered as a flat dose of 480 mg over approximately 60-minutes via IV infusion
Study: NCT03750708

Intervention type: DEVICE
Group type: OTHER
Intervention: Ara® KOLIBREE tooth brush
Description: Use of the Ara® KOLIBREE tooth brush by the child one month before alveolar bone graft up to the time of surgery.~The Ara® KOLIBREE tooth brush saves brush tracking data.
Study: NCT03734276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity activity
Description: Cyclo-ergometer session in high intensity setting
Study: NCT01646853

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Megavoltage photon beam
Description: initial dose:50Gy/2Gy/25f,5days/week escalation dose:4Gy/2Gy/2f

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin-fluorouracil chemotherapy
Description: cisplatin 75 mg/m2 on day 1 with standard hydration fluorouracil 1000 mg/m2/day1 i.v. by continuous infusion from day 1 to day 4 of each cycle
Study: NCT01565811

Intervention type: PROCEDURE
Intervention: perihepatic lymphadenectomy
Description: Hepatic pedicle lymph node dissection according to the protocol of the prospective multicentric study.Namely the six main groups of lymph nodes removed (HA,hepatic artery; CA, celiac axis; BD, common bile duct).
Study: NCT03734276

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control arm
Description: Usual care
Study: NCT03212924

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pupillometry
Description: Measure of pupil dilatation simultaneously to the evaluation of speech intelligibility. The variation of the pupil size is monitored during the presentation of speech stimuli in quiet and in the presence of a background noise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation of speech comprehension in quiet
Description: Three lists of 17 monosyllabic words (Lafon) are presented in quiet at 65 dB SPL. Listeners have to repeat what they understood. The results correspond to the percent of phonemes correctly identified.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation of speech comprehension in noise
Description: Three lists of 17 monosyllabic words (Lafon) are presented in a wide band noise at 65 dB SPL with a SNR (signal to noise ratio) of +10 dB. Listeners have to repeat what they understood. The results correspond to the percent of phonemes correctly identified.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOCA
Description: The Montreal Cognitive Assessment (MoCA) is a screening instrument to detect cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. The time to administer the MoCA is approximately 10 minutes. The total possible score is 30 points. The test suggests the existence of a cognitive impairment if the participant scores less than 26 points. The test is presented on a single sheet of paper.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: auto evaluation of listening effort in quiet
Description: The participant has to represent, on a continuous line, the amount of listening effort he used when listening to the monosyllabic words presented in quiet. A score from 0 (no listening effort) to 10 (effort maximum) is extracted from his response.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: auto evaluation of listening effort in noise
Description: The participant has to represent, on a continuous line, the amount of listening effort he used when listening to the monosyllabic words presented in the background noise. A score from 0 (no listening effort) to 10 (effort maximum) is extracted from his response.
Study: NCT04453371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator
Description: In the study group, tPA (Alteplase) 25 mg i/v over 2 hours, followed by a 25 mg tPA infusion over the subsequent 22 hours. After the end of thrombolytic therapy, unfractionated heparin is administered i/v at a starting dose of 10 units / kg per hour. The target value of PTT is 40C-50C.~In both groups patient's transfer from the heparin infusion to the introduction of low-molecular-weight heparins is performed after normalization of the D-dimer level.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ringer solution
Description: In the control group, an equivalent amount of Ringer's solution is administered. After 24 hours, the heparin infusion gets started, similar the described for study group.~In both groups patient's transfer from the heparin infusion to the introduction of low-molecular-weight heparins is performed after normalization of the D-dimer level.
Study: NCT05236049

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SclerFIX
Description: Chemically-treated, viro-inactivated, freeze-dried and irradiated umbilical cord lining membrane allograft used as substitute for scleral graft in support of intraocular implant.
Study: NCT03037775

Intervention type: OTHER
Group type: OTHER
Intervention: Baseline
Description: measurement of baseline hemodynamic parameters

Intervention type: DEVICE
Group type: OTHER
Intervention: e-cigarette without nicotine
Description: measurement hemodynamic parameters during smoking e-cigarette without nicotine

Intervention type: DEVICE
Group type: OTHER
Intervention: e-cigarette with nicotine
Description: measurement hemodynamic parameters smoking e-cigarette with nicotine

Intervention type: DEVICE
Group type: OTHER
Intervention: traditional cigarette
Description: measurement hemodynamic parameters smoking traditional cigarette
Study: NCT01696084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: First induction: 100 units/m2 by 90-minute IV infusion on Days 1, 3, 5. Second induction: 100 units/m2 by 90-minute IV infusion on Days 1 and 3. Consolidation therapy: 65 units/m2 by 90-minute IV infusion on Days 1 and 3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 7+3 (cytarabine and daunorubicin)
Description: First induction: 7+3 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 7 by continuous infusion, and daunorubicin at a dose of 60 mg/m2/day on Days 1, 2, and 3.~Second induction: 5+2 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 5 by continuous infusion and daunorubicin at a dose of 60 mg/m2/day on Days 1 and 2.~Consolidation therapy: 5+2 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 5 by continuous infusion, and daunorubicin at a dose of 60 mg/m2/day on Days 1 and 2.
Study: NCT03543475

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: arabin pessary
Description: arabin pessary: silicon device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: no pessary
Description: control group
Study: NCT02099578

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 25 g of Freeze-dried Strawberry Powder
Description: Participants will be given one packet of 25 g of freeze-dried strawberry powder and one packet of 25 g of placebo powder and asked to consume one packet in the morning and one at night.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 50 g of Freeze-dried Strawberry Powder
Description: Participants will be given two packets of 25 g of freeze-dried strawberry powder and asked to consume one packet in the morning and one at night.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Powder
Description: Participants will be given two packets of 25 g of placebo powder and asked to consume one packet in the morning and one at night.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Powder
Description: Participants will be given two packets of 25 g of placebo powder and asked to consume one packet in the morning and one at night.
Study: NCT03811028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOBI003
Description: weekly i.v. infusion
Study: NCT01748084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Days 1 and 15, rituximab 1 gramme plus 100 mg methylprednisolone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NaCl)
Description: Days 1 and 15, NaCl 500 ml plus 100 mg methylprednisolone
Study: NCT04342156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate 200 milligram (mg) Tab
Description: Oral tablet of Hydroxychloroquine sulfate

Intervention type: DRUG
Group type: OTHER
Intervention: Hydroxychloroquine Sulfate 200 milligram (mg) Tab
Description: Oral tablet of Hydroxychloroquine sulfate
Study: NCT02033681

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Saline solution is injected into the tissue as a placebo control.
Study: NCT02423525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Study: NCT02429804

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced Magnetic Resonance Imaging
Description: Undergo contrast-enhanced MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 Sodium Fluoride
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo PET/MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/MRI
Study: NCT04059081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab is provided as single-use vials for intravenous administration only. Obinutuzumab 1000mg fixed dose will be administered Chlorambucil would be provided as oral tablet with dose of 0.5mg/kg~Day 1 to day 28 is considered one cycle, and cycles will be repeated every 4-weeks, until 6 cycles.
Study: NCT00578851

Intervention type: DEVICE
Intervention: C2a - Taper™ Acetabular System
Description: The C2a-Taper™ Acetabular System is a ceramic on ceramic hip articulating system. The bearing surfaces consist of ceramic femoral heads and acetabular liners.
Study: NCT01388179

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: low-frequency rTMS to the left DLPFC prior to high-frequency deep rTMS to the FFA through the STS.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: low-frequency rTMS to the left DLPFC prior to high-frequency deep rTMS to the FFA through the STS.
Study: NCT02458677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX003
Study: NCT04894851

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Participants in the current study will receive contingencies for improvement in clutter, as measured by a trained, independent in-home rater. Ratings will be completed by after study consent, and once every month thereafter, being conducted at weeks 0, 4, 8, 12, and 16 of treatment. Participants will be reimbursed for each new 1-point reduction in CIR score, a set dollar amount per month for each CIR point reduction they maintain from baseline. Therefore, a perfectly performing patient would earn reimbursement (A CIR reduction of 8 points made in the first month and maintained throughout treatment. If a CIR score is higher than the prior month, the reinforcement schedule will reset to zero.
Study: NCT02576548

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4276
Description: MEDI4276 is an investigational product

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4276
Description: MEDI4276 is an investigational product

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4276
Description: MEDI4276 is an investigational product

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4276
Description: MEDI4276 is an investigational product

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4276
Description: MEDI4276 is an investigational product

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4276
Description: MEDI4276 is an investigational product

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4276
Description: MEDI4276 is an investigational product

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4276
Description: MEDI4276 is an investigational product

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4276
Description: MEDI4276 is an investigational product
Study: NCT04014699

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified 2.2mm microincision
Description: enlarging the internal incision about 0.4mm for conventional 2.2mm coaxial microincision phacoemulsification

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional 2.2mm microincision
Description: conventional 2.2mm coaxial microincision phacoemulsification